Volume 11, Issue 4, April – 2026 International Journal of Innovative Science and Research Technology
ISSN No: -2456-2165 https://doi.org/10.38124/ijisrt/26apr1279

AI-Guided Nanobots for Overcoming the Blood-Brain Barrier

Shweta Maury[1]; Patel Shrusti[2]; Joshi Darshil[3]

[1,2,3]Pharmacy, Sal College of Pharmacy, GTU, Ahmedabad, Gujarat, India

Publication Date: 2026/04/23

Abstract: The Blood–Brain Barrier (BBB) is a highly specialized structure formed by brain microvascular endothelial cells, pericytes, astrocytic end-feet, and the basement membrane, collectively constituting the neurovascular unit (NVU). While essential for maintaining cerebral homeostasis, the BBB poses a major challenge for treating central nervous system (CNS) disorders by severely limiting drug penetration through tight junctions, metabolic enzymes, and efflux transporters.

This review highlights the emerging potential of nanobots integrated with Artificial Intelligence (AI) as a transformative strategy to overcome BBB-related drug delivery limitations. Nanobots—nanoscale robotic systems typically 50–100 nm in size—are engineered for precise tasks such as targeted drug delivery and controlled navigation within biological environments. AI significantly enhances nanobot functionality by optimizing design parameters, controlling movement, and improving therapeutic outcomes. Machine learning approaches, including artificial neural networks (ANNs), enable predictive modelling of nanobot stability, drug release profiles, and BBB permeability. Advanced AI techniques such as hierarchical deep reinforcement learning (DRL) further support real-time tracking, localization, and autonomous navigation in complex physiological conditions. Additionally, AI-driven analysis of patient-specific data facilitates personalized neurotherapeutic strategies through optimized nanobot design and dosing.

The convergence of nanotechnology and AI holds promise for precise and effective treatment of neurological disorders, including brain tumors, neurodegenerative diseases, ischemic stroke, traumatic brain injury, and CNS infections. By integrating current advancements and identifying future research directions, this review underscores the growing significance of intelligent nanomedicine in neurotherapeutics.

Keywords: *Artificial Intelligence; Nanobots; Blood–Brain Barrier; Targeted Drug Delivery; CNS Drug Delivery.*

How to Cite: Shweta Maury; Patel Shrusti; Joshi Darshil (2026), AI - Guided Nanobots for Overcoming the Blood–Brain Barrier. *International Journal of Innovative Science and Research Technology*, 11(4), 1627-1644.
https://doi.org/10.38124/ijisrt/26apr1279

I. INTRODUCTION

The blood-brain barrier presents a significant hurdle in the effective treatment of central nervous system diseases, severely limiting the delivery of therapeutic agents to the brain. This review explores the groundbreaking potential of nanobots, coupled with artificial intelligence, to overcome this formidable obstacle. Nanobots offer novel mechanisms for targeted drug delivery and navigation within the brain, while AI provides the intelligence needed to optimize their design, control their movement, and enhance their therapeutic efficacy. Together, these technologies promise to revolutionize the landscape of neurotherapeutics, enabling precise and effective treatments for a wide range of brain disorders.

- *The Blood-Brain Barrier: A Formidable Obstacle for CNS Drug Delivery*

The Blood-Brain Barrier (BBB) is a complex structure essential for maintaining the homeostasis of the central nervous system (CNS), primarily composed of brain microvascular endothelial cells, pericytes, astrocytic end-feet, and the basement membrane, collectively forming the neurovascular unit (NVU) [1–3]. Endothelial cells are pivotal, exhibiting unique tight junctions that restrict permeability and selectively regulate the passage of molecules, thereby protecting the brain from harmful substances [4]. Pericytes and astrocytes contribute to BBB integrity and functionality through signaling pathways, such as the Wnt/β-catenin pathway, which is crucial for maintaining the barrier's properties [3]. The basement membrane, although less studied, plays a significant role in supporting the structural integrity of the BBB and facilitating cellular interactions necessary for its function [5]. Together, these components ensure that essential nutrients enter the CNS while preventing the infiltration of toxins, thus safeguarding neuronal function [2,4].

The primary mechanisms limiting drug permeation across the blood-brain barrier (BBB) include structural, enzymatic, and transport-related factors. The BBB is characterized by tight junctions formed by claudins and zonula occludens, which create a highly selective barrier with transendothelial electric resistance significantly higher than that of peripheral tissues [6]. Additionally, the presence of astrocytic foot processes and pericytes further restricts paracellular diffusion of large or polar molecules [6,7]. Enzymatic barriers, including various phosphatases, metabolise compounds attempting to cross the BBB, thereby limiting their availability in the brain [6].

Furthermore, efflux transporters actively remove drugs from the brain, while factors such as metabolic clearance and plasma protein binding also affect drug distribution within the central nervous system [8,9]. Understanding these mechanisms is crucial for developing effective therapies for neurological disorders [7,10].

The efficacy of conventional drug delivery methods in treating brain diseases is significantly limited by several critical factors, primarily the challenges posed by the blood-brain barrier (BBB). This barrier restricts the entry of therapeutic agents, making it difficult for drugs to reach their intended targets within the central nervous system (CNS). The following sections outline the primary factors contributing to these limitations.

➢ *Blood-Brain Barrier (BBB) Challenges*

- *Selective Permeability:*
The BBB is composed of tightly packed endothelial cells that selectively allow nutrients while blocking harmful substances, including many drugs [11].

- *Transport Mechanisms:*
Conventional drugs often fail to utilize the specific transport pathways (e.g., transcytosis) necessary for effective delivery across the BBB [12].

➢ *Alternative Barriers*

- *Additional Barriers:*
Besides the BBB, the blood-cerebrospinal fluid barrier and cellular barriers further complicate drug delivery, limiting the distribution of therapeutic agents [13].

- *Route of Administration:*
The effectiveness of various administration routes (e.g., intravenous, intranasal) is inconsistent, with many failing to achieve adequate drug concentrations in the brain [13,14].

➢ *Technological Limitations*

- *Conventional Systems:*
Traditional drug delivery systems often release drugs into general circulation, which is ineffective for CNS diseases like Alzheimer's and Parkinson's [14].

- *Need for Innovation:*
There is a pressing need for novel drug delivery systems, such as nanoparticles and other advanced technologies, to overcome these barriers [11].

While these challenges are significant, ongoing research into innovative drug delivery methods offers hope for improving treatment efficacy for brain diseases. However, the complexity of the BBB and other barriers necessitates continued exploration of alternative strategies.

This review offers a comprehensive interdisciplinary focus on the cutting-edge integration of nanobots, artificial intelligence, and strategies for navigating the blood-brain barrier, all aimed at revolutionizing the treatment of specific neurological disorders such as brain tumors, neurodegenerative conditions, ischemic stroke, traumatic brain injury, and brain infections.

II. FUNDAMENTALS OF NANOBOTS FOR CENTRAL NERVOUS SYSTEM DELIVERY

This section will delve into the core principles of nanobot design, materials, propulsion, and their strategies for interacting with and permeating the BBB.

➢ *Basic Principles and Design Considerations of Nanobots*

- *Definition:*
Nanobots are said to be tiny robots, they are usually 50-100 nanometers wide and that is very tiny about, 1000 times smaller than a red blood cell. Nanobots are nanorobotic machinery which are designed to work or perform very particular or we can say very specific tasks in the human body. The other name or form of nanobots is also called miniaturization. It means that something is as small as a grain of sand or a micrometer. These micro-robots move inside the body using magnetic or we can say acoustic signals which don't need any wires or batteries [15]. The element which is commonly used in the creation of Nano robots from which one is carbon is because it has some special properties that make it very useful at the Nano scale. Carbon is also known for being chemically stable and it doesn't easily react with other substances. There are two important forms of carbon which are used in nanotechnology are diamond and fullerene (also called Bucky Balls) [16]. To study Nanorobots more accurately the scientists use high-tech tools such as Scanning Electron Microscopy (SEM) which researches to create detailed images of the surface of nanorobots by scanning them with a focused beam of electrons. Another tool is Automatic Force Microscopy (AFM). It uses a tiny probe to feel the surface by understanding its shape and texture at the molecular scale.

- *Types of Nanobots:*
There are different types of designs and there are many different types of purpose and functionality of the different nanobots. Some of the major types of nanobots are: -

✓ *Respirocytes:*
They are used to be artificial oxygen carrying robots which work like red blood cells in our body. They carry out carbon dioxide and carry oxygen to the different parts of the

body. They use to carry oxygen through the tiny oxygen tanks towards the bloodstream.

✓ *Microbivores:*

They are called the fighters they use to fight against the infection and they are designed in such a way like the white blood cells. These nanobots don't need any antibiotics; they break the micro-organism into small parts and remove them from the body.

✓ *Pharmacytes:*

These nanobots use to attack at the specific targeted areas and use to carry medicines at the targeted area and use to release them due to which they make the treatment more effective. They are also known as smart couriers because they deliver the drug at the correct targeted place.

✓ *Clottocytes:*

These nanobots are known for their healing ability. They act like platelets in our blood due to which whenever we get a cut they help in clotting. They quickly clot and heal the wound area. They are mainly used in surgeries or any medical emergency.

✓ *DNA Nanobots:*

Its main function is to deliver the medicine, target disease and data gathering of the body condition. These nanobots are made from the DNA strands and used to work at the molecular level. They are very intelligent and follow all the instructions.

✓ *Magnetic Nanobots:*

These Nanobots have the magnetic field due to which they are signaled and guided toward the targeted way. Their main function is to reach the sensitive parts where normal tools can't be able to go like the brain or eyes etc. Due to which they can give the drugs to clear the blockage or infection.

✓ *Sensor Nanobots:*

These are those nanobots which gather all the data which is inside the body such as sugar level, temperature, number of toxins inside the blood and give all the data due to which the doctors can track all the wanted information from the body [15].

- *Mechanism for Navigating and Delivery:*

Micro or we can say nanobots are tiny machines that can use energy from their surroundings to move and do work.

✓ *How They Move:*

Some robots can be powered in different ways. Some get energy from magnetic fields, light, chemicals in the environments. This energy helps them move through liquids, twist, spin or similar how bacteria swim.

✓ *Moving Fast and Carrying Loads:*

Due to their small size, they can move quickly and also strong for their size and can pull or push objects much bigger than themselves.

✓ *Changing their Surface:*

The outer layer of these robots can be modified easily.

Some of the researchers add things which help them to avoid being attacked by the body, stick to certain cells, carry medicine or break apart after their job is done.

✓ *Reacting to Their Environment*:

Nanobots built to sense and react to changes around them might release medicine only when they reach a certain spot, or change their movement when they sense a specific chemical.

- *Simple Breakdown of Each Major Group by Their Way of Moving*

✓ *Nanodevices That Move Using Chemical Reaction:*

Some nanodevices have special coatings that react with certain chemicals. Now let us imagine a tiny ball with one side covered in platinum. When it's dropped into a liquid like hydrogen peroxide, the platinum side reacts and makes a little bubble. These bubbles act like tiny engines, pushing the ball forward, some have long tube shapes where bubbles from inside and shoot out, making the tube move. There are also robots that use enzymes found in living things, reacting with natural chemicals to get moving.

✓ *Nanodevices Moved by Outside Forces:*

Magnetic nanodevices are built with materials like iron or nickel. Doctors or Researchers steer them using magnets, making them wiggle or spin through fluids. Light-powered nanodevices are sensitive to certain types of light. When the light of a beam hits them, it triggers them to move or even changes their shape so they scoot along. Sound and electricity can also push these tiny devices, like a remote control that sends invisible waves to move them to where they're needed.

- *Potential field mechanism*

The idea comes from the natural system. For instance, birds flying in flocks or fish swimming in schools do not have a central leader telling them where to go. Instead, each one reacts to the movements and signals of others nearby or reacts to the environment. This coordinated behavior allows them to move together efficiently and adapt to changes instantly.

In the same way, potential fields give micro/nanorobots the ability to “sense” their surroundings and respond. The environment creates certain attractive or repulsive forces for example, a higher concentration of a chemical might “attract” the robots, while obstacles or healthy tissues might “repel” them. By following these invisible patterns, the robots can automatically move toward disease areas where treatment is needed and stay away from places where they might cause harm.

This approach offers several key benefits:

✓ *More Accurate Targeting*:

The robots can find the problem area on their own by following natural signals, which reduces the risk of damaging nearby healthy tissues.

- ✓ *Fewer Side Effects*:
  Since treatments are delivered right to target, patients experience less harm from medicines spreading to the wrong places.

- ✓ *Built in Safety and Reliability*:
  Because the robots work in swarms using group behavior, the system is not dependent on a single robot. If a few fail, others continue the job, ensuring the treatment still works effectively.

- ✓ *Flexibility In Changing Conditions*:
  Just like animals adapt to sudden changes in their surroundings, the robots can adjust to changing conditions inside the body without needing step by step instruction.

This process makes micro/nanorobots smarter and more adaptable. Instead of being controlled manually or centrally, they use the environment itself to guide their actions. This makes medical treatments not only more precise but also safer and more reliable.

- *Role of Microrobots design in Drug Loading and Release:*

Microbots are tiny machines that can be used to deliver medicines directly to a specific part of the body. They can carry drugs in two main ways: - either by holding the medicine inside them or by attaching small drug carriers to their surface. The way a microrobot carries and releases the drug often depends on its design and the type of medicine being used. Bigger microbots have the advantage of carrying larger amounts of medicine because they have more space inside them. This means they can deliver stronger doses to a target area, which can make treatments more effective. What makes microrobots even more useful is that they can be designed for different medical situations. For example, they can be built to release cancer drugs directly at a tumor, which lowers side effects on the rest of the body. They can also be designed to release substances that help repair tissues or fight infections. The way the drug is released can also be controlled -for example, through magnets, changes in body conditions like pH, or even by using light or ultrasound. In short, microrobots are flexible tools in medicine. By changing their size, structure, and the way they release drugs, they can be adjusted to suit different types of treatments, making them a promising option for future healthcare.

- *Next-Generation Nanobots: Combining Artificial and Biological Materials*

To make nanobots safer and more compatible with living systems, scientists have developed a special type called bio hybrid micro-and nanobots. Unlike traditional versions that rely only on metals, bio hybrid bots are partly made from biological substances. These can include proteins, enzymes, cell parts (like organelles), or even whole living cells. By combining synthetic material with biological ones, these hybrid robots can perform tasks in a more natural and less harmful way inside biological environments.

Another approach is to coat or combine these robots with biocompatible materials such as graphene, a strong and flexible carbon-based material. This makes them more stable, safe, and effective when used in medical applications.

Because of their unique design, bio hybrid nanobots are being explored for exciting application including:

- ✓ Precise drug delivery to specific tissues or tumors.
- ✓ Minimally invasive surgery or repair at the cellular level.
- ✓ Environmental cleanup, like breaking down pollutants.
- ✓ Diagnostic tasks, where they detect diseases by interacting with biological markers.
- ✓ In simple terms, while traditional nanobots are like tiny machines built only from metals, bio hybrid nanobots are “smart machines” that blend biology with technology, making them better suited for working in harmony with living systems [17].

- ➢ *Key Challenges and Opportunities in Nanorobot Development:*

The creation of real, fully functional nanorobots is a fascinating but extremely difficult goal. Right now, most of the work in this field is still happening at the level of computer models, design blueprints, and theoretical roadmaps rather than practical devices. Researches face several key barriers that slow down the development of working prototypes:

- *Movement and Control at the Nanoscale*

At such a tiny scale, traditional motors or engines do not work. Scientists need new ways to make nanorobots move and respond to their surroundings, but progress in building reliable actuation systems is still very limited. Some approaches being studied include using chemical fuels, magnetic fields, ultrasound, or even harnessing biological components like bacteria or flagella. However, each method has challenges related to energy supply, stability, precision and control.

- *Miniaturized Electronics and Information Processing*

For nanobots to do useful tasks, they must be able to sense their environment, collect signals, and process that information. This means they need nanoscale versions of circuits, chips and processing units. Unfortunately, current electronics are still difficult to shrink down enough while keeping them powerful and energy-efficient. Without this, it's hard for nanorobots to make autonomous decisions, communicate, or navigate complex biological environments.

- *Nanoassembly and Manufacturing Techniques*

Building and arranging structures at the nanoscale is another major hurdle. Creating a single nanostructure is possible in labs, but assembling billions of them in a consistent, reliable, and cost- effective way -especially with the complexity needed for a robot -is extremely challenging. Techniques like self-assembly, DNA origami and 3D nanoprinting are promising, but they are still at an early stage of development.

The dream of nanorobots is still mostly in the planning and simulation phase because we don't yet have the technology to (a) move them efficiently, (b) give them fully functional nanosensors and signal-processing units, and (c) manufacture them at high precision and scale. Developing solutions in these three areas will be the key to making nanorobots a practical reality in medicine, environmental cleanup, and many other fields [18].

III. THE INTEGRAL ROLE OF ARTIFICIAL INTELLIGENCE IN NANOBOT- BASED DRUG DELIVERY

This section will delve into the transformative impact of AI on nanobot technology, highlighting its role in optimizing design, enabling real-time control and navigation, and predicting therapeutic outcomes. By integrating AI, nanobot-based drug delivery systems can achieve unprecedented levels of precision, efficiency, and adaptability, paving the way for personalized treatments of complex brain disorders.

➢ *AI for Intelligent Nanobot Design and Optimization*

Machine learning has dramatically evolved, advancing through four distinct phases: initial emergence, early development, rapid acceleration, and robust expansion [2]. The integration of machine learning techniques into the design of nanomaterials is revolutionizing the field of electronics. This is achieved through predictive modeling, which facilitates the enhancement of material properties and the optimization of device performance [20].

Optimizing machine learning algorithms to predict the stability of nanobots in various physiological environments involves leveraging advanced data-driven techniques and models. These methods focus on accurately simulating and predicting stability metrics, such as chemical potentials and zeta potentials, which are crucial for understanding nanobot behavior in complex environments. The integration of machine learning with physics-based approaches and the use of hyper-parameter optimization can significantly enhance prediction accuracy and computational efficiency.

- *Data-Driven Metrics:*

✓ Machine learning models, such as artificial neural networks (ANNs), support vector machines (SVMs), and multiple regression analyses (MRAs), are employed to predict stability metrics like zeta potential, which is critical for assessing nanobot stability in colloidal systems. ANNs have shown superior accuracy, achieving over 97% accuracy in predictions, making them a preferred choice for such tasks [21].
✓ Physics-based and machine learning-derived methods are used to predict stability metrics, including chemical potentials and cohesive energies, which are essential for designing thermodynamically stable nanostructures [22].

- *Stability-Aware Training:*

✓ Stability-Aware Boltzmann Estimator (StABlE) Training is a novel approach that combines supervised training with reference system observables to produce stable and accurate neural network interatomic potentials (NNIPs). This method iteratively corrects instabilities, enhancing the stability of molecular dynamics simulations [23].

- *Hyper-Parameter Optimization:*

✓ Hyper-parameter optimization (HPO) techniques are crucial for fine-tuning machine learning models, such as ANNs and SVMs, to improve their performance in predicting stability metrics. Proper tuning of these models can lead to significant improvements in prediction accuracy [24].
✓ While machine learning offers promising solutions for predicting nanobot stability, challenges remain in ensuring the models' generalizability across diverse physiological environments. The trade-off between stability and accuracy, as seen in robotic systems, highlights the need for careful model design to balance these aspects [25].

➢ *Generative AI Models for Novel Material Discovery and Nanobot Architecture Design:*

Employing generative artificial intelligence to efficiently discover novel materials with distinctive properties entails utilizing advanced computational techniques and sophisticated deep learning methodologies. These innovative models are designed to tackle the inverse design challenge, aiming to produce material structures that not only fulfill specific property criteria but also minimize the reliance on extensive computational resources. By synergizing generative models with property prediction and streamlined optimization strategies, researchers can expedite the discovery process and significantly enhance the efficiency of material design.

- *Conditional Generative Approaches:*

✓ Conditional generative models, such as those using diffusion models and autoencoders, can optimize the stability of atomic configurations by considering energy differences between stable and less stable polymorphs. This approach has shown promising results, with generated structures achieving up to 82% accuracy in meeting desired properties [26].
✓ These models utilize comprehensive material representations, including lattice parameters, atom types, and formation energy, to guide the generation process [26].

- *High-Throughput Screening and Biasing:*

✓ Combining generative models with supervised learning allows for the high-throughput screening of molecules, optimizing multiple properties simultaneously. This method eliminates the need for quantum chemical calculations, making it suitable for large-scale applications [27].
✓ By retraining generative models with molecules that exhibit desirable properties, researchers can bias the model towards generating more optimal candidates [27].

- *Advanced Generative Models:*

- ✓ Improved generative adversarial networks (GANs) have been developed to focus on the stability of generated materials, significantly increasing the efficiency of generating stable structures, as demonstrated in the case of vanadium oxide compositions [28].
- ✓ These models reduce the reliance on density functional theory (DFT) calculations by incorporating formation energy predictors, streamlining the discovery process [28].

- *Inverse Design and Latent Space Optimization:*

- ✓ Generative models can optimize physical properties in the latent space, allowing for the inverse design of materials with targeted properties. This approach has been successfully applied to binary systems and can be extended to multicomponent systems for multi- objective optimization [29].
- ✓ The exploration and manipulation of latent spaces in deep generative models enable the encoding of complex inorganic structures, facilitating the discovery of materials with specific technological applications [30].

- ➢ *High-Throughput Screening and Autonomous Synthesis Optimization Using AI:*

AI-driven high-throughput screening (HTS) significantly enhances the discovery of novel compounds in pharmaceutical research by integrating advanced computational techniques with traditional screening methods. This synergy accelerates the drug discovery process, improves the precision of identifying potential therapeutics, and expands the chemical space available for exploration. The following sections outline the key contributions of AI in this domain.

- *Accelerated Drug Discovery:*

- ✓ AI algorithms streamline the identification of lead compounds by analyzing vast datasets, reducing the time required for hit identification [31].

- ✓ Virtual screening can preselect target-specific compounds from extensive libraries, as demonstrated by a study that narrowed down 2.6 million compounds to just 434 for Sirtuin-1 inhibition, achieving a 12-fold higher hit rate [32].

- *Enhanced Compound Optimization:*

- ✓ AI facilitates the virtual generation of billions of synthetically feasible compounds, significantly increasing the success rate for synthesis to 80% [33].

- ✓ The integration of quantitative high-throughput screening (qHTS) with AI allows for the rapid profiling of compounds, leading to the identification of candidates with improved biological activity [33].

- *Cost Efficiency and Risk Reduction:*

- ✓ AI-driven approaches reduce the costs associated with traditional HTS by minimizing reagent use and labor, thus lowering the overall financial burden of drug discovery [34].
- ✓ Early predictions of biological activity and toxicity parameters help mitigate the risk of late- stage failures in clinical trials [34].
- ✓ Conversely, while AI-driven HTS offers numerous advantages, challenges such as data quality, algorithm transparency, and the need for interdisciplinary collaboration remain critical for maximizing its potential in pharmaceutical research.

- ➢ *AI-Driven Control and Navigation of Nanobots*
- *Real-time Localization and Tracking:*

AI-enhanced medical imaging can be optimized for precise nanobot visualization in various tissues and organs through the integration of advanced imaging techniques and intelligent Nano systems. This optimization involves leveraging the unique properties of nanomaterials and AI algorithms to improve imaging accuracy and specificity.

- *Nanoparticle-Based Contrast Modeling:*

- ✓ *Enhanced Sensitivity Specificity:*

Nanoparticles, such as quantum dots and magnetic nanoparticles, can be functionalized with specific ligands to target particular tissues, improving visualization accuracy and reducing false positives [35].

- ✓ *Responsive Behavior:*

Intelligent nanosystems can be engineered to respond to specific biomarkers, allowing for real-time monitoring of tissue micro-environments and enhancing the contrast in imaging [36].

- *Advanced Imaging Techniques:*

- ✓ *Magnetic Resonance Imaging (MRI):*

The use of magnetic nanoparticles in MRI can improve image quality and provide detailed insights into biological structures, although challenges in image analysis remain [37].

- ✓ *Phase Contrast Imaging:*

Techniques like Superimposed Wavefront Imaging of Diffraction-enhanced X-rays (SWIDeX) offer high spatial resolution for soft tissue visualization, crucial for accurate nanobot tracking [38].

- *AI Integration:*

- ✓ *Automated Analysis:*

AI algorithms can significantly reduce analysis time and enhance diagnostic accuracy by automatically identifying and classifying nanobots within imaging data [39].

While the advancements in AI-enhanced medical imaging present significant opportunities for improved nanobot visualization, challenges such as the biocompatibility of nanomaterials and the complexity of imaging mechanisms must be addressed to ensure effective clinical applications.

➢ *Autonomous Navigation and Targeting:*

Optimizing reinforcement learning (RL) algorithms for autonomous navigation in complex physiological environments, such as blood vessels and tissue matrices, involves several innovative strategies. These strategies focus on enhancing the adaptability and efficiency of microrobots navigating through intricate biological landscapes.

- *Hierarchical Control Schemes:*

✓ *Decoupled Components:*

Implementing a hierarchical control scheme with high-level and low-level controllers allows for efficient navigation. The high-level controller sets dynamic targets, while the low-level deep reinforcement learning (DRL) controller maneuvers the micro robots towards these targets using 3D convolutional neural networks [40,41].

✓ *Robustness to Perturbations:*

This approach has shown resilience against various disturbances, such as blood flow and cellular density, which are prevalent in vascular environments [40].

- *Integration with Evolutionary Computation:*

✓ *Policy Search Optimization:*

Combining RL with evolutionary computation enhances policy search robustness. This hybrid approach allows for better exploration of the policy space, reducing the likelihood of local optima and improving navigation performance in complex environments [42].

- *Adaptive Planning Frameworks:*

✓ *Real-Time Decision Making:*

Integrating RL with adaptive planning algorithms addresses the challenges of dynamic and unstructured environments. This combination enhances the system's ability to adapt to real-time changes, improving overall navigation efficiency [43].

While these advancements show promise, challenges remain in achieving fully autonomous navigation in highly dynamic environments. Future research may focus on refining these algorithms to further enhance their adaptability and efficiency in real-world applications.

✓ *Feedback Control Systems:*

The integration of AI-powered in situ biosensors significantly enhances the accuracy of environmental sensing within Feedback Control Systems by leveraging advanced data analysis and real-time monitoring capabilities. This synergy allows for improved detection of environmental changes, leading to more effective management and response strategies.

- *Enhanced Data Analysis:*

✓ *Machine Learning Algorithms:*

AI models, particularly recurrent neural networks (RNNs), analyze data from multiple biosensors to identify patterns and predict trends in environmental conditions, such as water quality [44].

✓ *Real-Time Processing:*

AI facilitates the rapid processing of data, enabling immediate responses to detected changes, which is crucial for maintaining environmental integrity [45].

- *Improved Sensor Capabilities:*

✓ *Biosensor Functionality:*

The integration of AI enhances the selectivity and efficiency of biochemical sensors, allowing for more accurate detection of pollutants and other environmental parameters [46].

✓ *Cost-Effectiveness:*

AI-driven biosensors can achieve high sensitivity and precision at lower costs, making them accessible for widespread environmental monitoring [47].

✓ *Future Perspectives:*

While the integration of AI in biosensing offers substantial benefits, challenges remain in terms of sensor commercialization and the need for robust communication protocols to ensure effective data exchange between systems [46]. This highlights the ongoing need for research and development in this field.

➢ *AI for Pharmacokinetic/Pharmacodynamic (PK/PD) Modeling and Personalized Medicine*

The application of predictive analytics in drug distribution, metabolism, and therapeutic efficacy is influenced by several key factors, including biological characteristics, chemical structure, and advanced computational techniques. Understanding these factors is essential for optimizing drug development and enhancing therapeutic outcomes.

- *Biological Factors*

✓ *Subcellular Distribution:*

Drug efficacy is closely linked to its distribution within organelles, which can selectively accumulate or exclude drugs based on their physicochemical properties [48].

✓ *Metabolic Pathways:*

The metabolism of drugs can yield metabolites with different pharmacological properties, impacting both safety and efficacy. Predicting these metabolic pathways is crucial to avoid clinical attrition [49,50].

- *Chemical Structure*

✓ *Structure-Activity Relationships:*

The chemical structure of a drug determines its pharmacokinetics and pharmacodynamics. Approaches like quantitative structure-property relationships (QSPR) and physiologically based pharmacokinetic (PBPK) models are vital for predicting drug disposition [51].

- *Computational Techniques*

✓ *Machine Learning AI:*

The integration of machine learning and AI in predictive analytics allows for the analysis of complex biological data, improving the accuracy of drug efficacy predictions and reducing development costs [50,52].

While predictive analytics offers significant advantages in drug development, challenges remain, such as the need for robust validation frameworks and the ethical implications of AI in healthcare. These factors must be addressed to fully realize the potential of predictive analytics in enhancing drug efficacy and safety.

➢ *AI-Driven Patient Data Analysis to Tailor Nanobot Design and Dosage for Personalized Treatment:*

AI-driven analysis of patient data significantly influences the development of nanobots for targeted therapy by enhancing precision, personalization, and efficacy in treatment strategies. This integration allows for the design of nanobots that can autonomously navigate the body, target specific cells while minimize side effects.

- *Enhanced Precision in Targeting*

✓ AI algorithms analyze patient-specific data, including genetic and clinical information, to optimize the design and functionality of nanobots [53].
✓ For instance, nanobots can be engineered to identify and interact with cancer cells through biomarker analysis, improving targeting accuracy [54].

- *Personalized Treatment Plans*

✓ AI facilitates the creation of personalized treatment plans by evaluating individual patient factors, such as medical history and imaging results [55].
✓ This approach ensures that nanobots deliver therapeutic agents tailored to the specific tumor type and location, enhancing treatment effectiveness [56].

- *Improved Outcomes and Reduced Side Effects*

✓ The use of AI in conjunction with nanotechnology allows for real-time adjustments in treatment strategies, leading to better patient outcomes and reduced adverse effects [57].
✓ AI-driven simulations can refine nanobot navigation, ensuring optimal delivery of drugs to affected areas while sparing healthy tissues [54].
✓ Conversely, while AI and nanotechnology hold great promise for revolutionizing targeted therapies, challenges such as data integration, ethical considerations, and regulatory hurdles remain significant barriers to widespread implementation.

➢ *AI in Data Analysis and Interpretation from Preclinical Studies*

The integration of automated analysis of imaging data, histological sections, and omics data can significantly enhance the accuracy of efficacy and safety assessments in pharmaceutical research. By leveraging advanced technologies, researchers can obtain a comprehensive understanding of drug behavior and its effects on biological systems, ultimately leading to improved drug development outcomes.

- *Integration of Omics Data:*

✓ *Omics Technology:*

Transcriptomics, proteomics, and metabolomics provide insights into molecular pathways related to drug toxicity, enabling early identification of adverse effects [58].

✓ *Predictive Modeling:*

Machine learning and quantitative structure–activity relationship (QSAR) models enhance the prediction of toxicity endpoints, facilitating safer drug design [58].

- *Automated Histological Analysis:*

✓ *AI in Histopathology:*

User-friendly AI systems allow non-experts to analyze histopathology images, generating quantitative results that can be tracked and visualized interactively [59].

✓ *Data Provenance:*

Automated cataloging of analysis outputs ensures data integrity and facilitates interdisciplinary collaboration in drug development [59]

- *Mass Spectroscopy Imaging (MSI):*

✓ *Spatial Resolution:*

MSI enables the visualization of drug distribution and metabolism in tissues, providing critical pharmacokinetic data without losing spatial context [60].

✓ *High-Throughput Screening:*

MSI can be applied in early drug R&D stages, enhancing the understanding of drug efficacy and safety through detailed molecular mapping [60].

While the integration of these technologies presents significant advantages, challenges remain in standardizing methodologies and interpreting complex biological interactions, necessitating ongoing collaboration among researchers, clinicians, and regulatory bodies [58].

➢ *Identification of New Biomarkers for Disease Progression and Treatment Response:*

Machine learning algorithms and omics technologies significantly enhance the discovery of new biomarkers for disease progression and treatment response. By integrating vast datasets from various omics fields, these technologies facilitate the identification of novel biomarkers that can lead to personalized medicine approaches. The following sections outline the key contributions of these technologies.

- *Integration of Omics Data*

✓ *Multi-Omics Profiling:*

Combining genomics, proteomics, and metabolomics allows for a comprehensive understanding of disease mechanisms, enabling the identification of biomarkers that reflect complex biological processes [61].

✓ *Data-Driven Insights:*

Machine learning algorithms analyze large-scale omics datasets to uncover patterns associated with disease states, improving the accuracy of predictions regarding disease progression and treatment outcomes [62].

- *Machine Learning Applications*

✓ *Predictive Modeling:*

ML techniques enhance the prediction of cancer subtypes and treatment responses by analyzing genomic information, such as mutations and expression profiles [62].

✓ *User-Friendly Tools:*

Platforms like OmicLearn democratize access to machine learning for biomarker discovery, allowing researchers without extensive programming skills to utilize advanced algorithms [63].

- *Challenges and Considerations*

Despite the advancements, challenges such as data bias and the need for diverse datasets persist. Addressing these issues is crucial for the equitable application of AI and ML in biomarker discovery [64].

In contrast, while machine learning and omics technologies offer promising avenues for biomarker discovery, traditional methods still play a role in validating these findings, emphasizing the need for a balanced approach in clinical research.

IV. NANOBOT-MEDIATED TREATMENT OF BRAIN DISEASES: CURRENT STATUS AND FUTURE PROSPECTS

This section will detail specific applications of nanobots, powerfully enhanced by AI, for various neurological disorders. By exploring how AI revolutionizes nanobot development and operation— from design and optimization to real-time control, navigation, and outcome prediction— this review illuminates the exciting potential of personalized medicine in treating complex brain disorders.

➢ *Brain Tumors (e.g., Glioblastoma Multiforme, Metastatic Brain Cancer)*

Recent advancements in nanotechnology have significantly enhanced the targeted delivery of chemotherapeutics and gene therapy agents, offering promising solutions to the limitations of Conventional cancer treatments. Nanocarriers such as liposomes, dendrimers, and polymeric nanomaterials have been developed to improve drug bioavailability and minimize systemic toxicity by delivering therapeutic agents directly to tumor sites. These advancements not only enhance the efficacy of chemotherapeutic agents but also facilitate the delivery of biological macromolecules like therapeutic antibodies and genes, which are gaining attention in cancer therapy. The following sections detail the key advancements in this field.

- *Nanocarrier Systems*

✓ *Liposomes and Dendrimers:*

These are used for encapsulating chemotherapeutic agents, improving their pharmacokinetics and bioavailability, and reducing damage to healthy tissues [65,66].

✓ *Polymeric Micelles and Carbon Nanotubes:*

These systems enhance the delivery of drugs by improving their solubility and stability, allowing for more effective targeting of tumor cells [67].

✓ *Mesoporous Silica Nanoparticles (MSNs):*

Recent advancements include the development of MSNs, which offer high drug loading capacity and controlled release properties [67].

- *Gene Therapy and Molecular Imaging*

✓ *CRISPR/Cas9-based Nanotherapy:*

This approach utilizes nanoparticles for precise gene editing, offering a novel method for cancer treatment [68].

✓ *Quantum Dots and Nanosensors:*

These tools enable precise identification of cancer biomarkers, aiding in early detection and diagnosis [66].

- *Challenges and Future Directions*

✓ *Biocompatibility and Toxicity:*

Despite the potential of nanotechnology, challenges such as nanoparticle toxicity and biocompatibility remain significant hurdles [66,68].

✓ *Regulatory and Clinical Translation:*

The complexity of regulatory approval and clinical translation of these technologies continues to hinder their widespread adoption [66,68].

While nanotechnology offers innovative solutions for targeted drug delivery, it is crucial to address the challenges of safety, regulatory approval, and scalability to fully realize its potential in cancer therapy. Continued research and development in this field are essential to overcome these obstacles and enhance the effectiveness of nanomedicine.

➢ *AI-Enhanced Precision in Identifying Tumor Boundaries and Optimizing Drug Distribution within Heterogeneous Tumor Microenvironments*

AI-enhanced precision in identifying tumor boundaries significantly improves treatment outcomes for cancer patients by facilitating more accurate diagnoses and personalized treatment plans. This advancement allows for better delineation of tumor margins, which is crucial for effective surgical interventions and targeted therapies. The following sections elaborate on the key aspects of this improvement.

- *Enhanced Diagnostic Accuracy*

✓ AI algorithms improve the precision of medical imaging, leading to more accurate tumor identification and characterization [69].
✓ Studies show that AI can reduce false positives in cancer screenings, such as prostate cancer, by up to 50% [70].

- *Optimized Treatment Planning*

✓ AI-driven tools enable precise tumor boundary delineation, which is essential for planning radiotherapy and minimizing damage to surrounding healthy tissues [69].
✓ Personalized therapy plans are developed by analyzing complex datasets, including genomic and clinical data, allowing for tailored treatment strategies [71].

- *Improved Patient Outcomes*

✓ The integration of AI in treatment planning has been linked to reduced treatment delays and enhanced clinical outcomes [70].
✓ AI models predict patient responses to therapies, leading to more effective and individualized treatment regimens [72]
✓ Conversely, while AI shows promise in improving treatment outcomes, challenges such as data quality and ethical considerations remain significant barriers to its widespread adoption in clinical practice. Addressing these issues is crucial for realizing the full potential of AI in oncology.

➢ *Neurodegenerative Diseases (e.g., Alzheimer's, Parkinson's, Huntington's, ALS)*

Nanobots can be engineered to deliver neurotropic factors to targeted neurons in the brain by utilizing advanced biomimetic designs and targeted delivery systems. These nanobots can effectively cross the blood-brain barrier (BBB) and release therapeutic agents at specific sites, addressing challenges in treating neurodegenerative diseases.

- *Nanobot Design and Functionality*

✓ *Biomimetic Carriers:*

Nanocarriers inspired by biological systems, such as lipoproteins, can encapsulate neurotropic factors like brain-derived neurotrophic factor (BDNF) and enhance their delivery across the BBB [73].

✓ *Polymer Nanoparticles:*

Synthetic polymer nanoparticles can facilitate the transport of large molecules like BDNF into the brain by mimicking a "Trojan horse" mechanism, allowing for effective penetration into brain tissue.

- *Targeting Mechanisms*

✓ *Functionalization:*

Nanobots can be functionalized with specific peptides (e.g., Apolipoprotein E3) to target damaged cerebral vasculature, improving delivery efficiency to affected neurons [73].

✓ *Closed-Loop Systems:*

Implantable nanosystems equipped with sensors can monitor neurotransmitter levels and adjust the delivery of neurotrophic factors in real-time, ensuring precise therapeutic intervention [74].

- *Challenges and Considerations*

While the engineering of nanobots for neurotrophic factor delivery shows promise, challenges remain, such as ensuring biocompatibility and minimizing potential toxicity. Additionally, the complexity of the BBB and individual patient variability necessitate further research to optimize these systems for clinical use [75,76].

➢ *AI for Optimizing Delivery to Specific, Deep Brain Regions Affected by Neurodegeneration:*

Machine learning algorithms play a crucial role in optimizing the navigation and targeting of nanobots for treating neurodegenerative diseases by enhancing their ability to cross the blood-brain barrier (BBB) and deliver therapeutic agents effectively. These algorithms can analyze vast datasets to predict optimal nanoparticle designs and their interactions with neural tissues, thereby improving treatment outcomes.

- *Machine Learning in Nanobot Design*

✓ *Data Integration:*

Machine learning techniques, such as Information Fusion and Perturbation Theory, can consolidate diverse datasets, enabling the identification of promising nanoparticle candidates for drug delivery systems [77].

✓ *Predictive Modeling:*

Algorithms like Artificial Neural Networks (ANN) have shown high sensitivity and specificity in predicting the efficacy of nanoparticle formulations, achieving an Area Under the Receiver Operating Curve (AUROC) of approximately 0.93 to 0.95 [77].

- *Targeting Mechanisms*

✓ *Controlled Maneuvering:*

Machine learning aids in developing algorithms that allow nanobots to navigate complex brain environments, ensuring precise targeting of affected areas, such as those impacted by Alzheimer's or Parkinson's diseases [75,78].

✓ *Real-time Adaptation:*

AI can facilitate real-time adjustments in navigation strategies based on feedback from the brain's biochemical environment, enhancing the effectiveness of drug delivery [79].

- *Challenges and Future Directions*

✓ *Data Limitations:*

The effectiveness of machine learning is often constrained by the limited availability of comprehensive datasets on nanoparticle interactions with neural tissues [77].

✓ *Ethical Considerations:*

The integration of nanobots in human neural circuits raises ethical questions regarding safety and long-term effects, necessitating careful consideration in future research [79].

While machine learning offers significant advancements in nanobot navigation and targeting, the challenges of data scarcity and ethical implications must be addressed to fully realize its potential in treating neurodegenerative diseases.

➢ *Emerging Applications in Psychiatric and Other Neurological Disorders*

Traditional psychotropic drug delivery methods face significant limitations, primarily due to low efficiency and high systemic side effects. These methods often result in less than 1% of the drug reaching the target site, with the remainder causing unintended effects throughout the body. Nanobots offer a promising solution by providing targeted delivery, thereby increasing efficiency and reducing side effects. This approach leverages the ability of nanobots to navigate directly to the target site, enhancing drug retention and effectiveness.

- *Limitations of Traditional Drug Delivery*

✓ *Low Efficiency:*

Traditional methods often result in less than 1% of the drug reaching the intended target, leading to significant wastage and reduced therapeutic effects [80].

✓ *Systemic Side Effects:*

The majority of the drug disperses throughout the body, causing adverse effects unrelated to the treatment goal [80].

✓ *Bioavailability and Degradation:*

Many drugs suffer from poor bioavailability and are susceptible to degradation before reaching the target site [81].

- *Advantages of Nanobot Drug Delivery*

✓ *Targeted Delivery:*

Nanobots can autonomously navigate to specific sites, such as tumors or diseased cells, ensuring that a higher concentration of the drug reaches the target [81,82].

✓ *Reduced Side Effects:*

By delivering drugs directly to the target, nanobots minimize exposure to healthy tissues, thereby reducing systemic side effects [83].

✓ *Enhanced Efficiency:*

Nanobots can dynamically adjust drug release rates based on local conditions, such as the concentration of tumor biomarkers, improving drug utilization [82].

- *Challenges and Future Directions*

While nanobots present a revolutionary approach to drug delivery, challenges remain, including their interaction within the human body and the need for standardized evaluation methods. Future advancements in artificial intelligence and mobile communication may further enhance the capabilities of nanobots, making them a viable alternative to traditional methods [83].

V. PRECLINICAL STUDIES, CLINICAL TRANSLATION, AND REGULATORY LANDSCAPE

Navigating the intricate landscape of brain diseases demands innovative therapeutic strategies, and nanobots, enhanced by artificial intelligence, offer a compelling solution. This section bridges the critical gap between groundbreaking research and tangible clinical applications, meticulously examining the current state of clinical development while addressing the multifaceted challenges of regulatory approval. As we transition from promising preclinical results to real-world clinical impact, a comprehensive understanding of the opportunities and obstacles ahead becomes not just essential, but transformative for the future of personalized medicine.

➢ *Progress in Clinical Trials: Bridging the Translational Gap*

Current nanobot-related therapies in clinical development for treating brain diseases primarily focus on enhancing drug delivery across the blood-brain barrier (BBB) and targeting specific neurological conditions such as brain cancer, Alzheimer's disease, and Parkinson's disease. Nanorobots facilitate active targeting and controlled release of therapeutics, significantly improving the precision of drug delivery to hard-to-reach brain lesions, thereby overcoming limitations of conventional therapies [66,67]. For instance, advancements in nanomedicine have led to the development of nanoparticle- based systems that can encapsulate drugs and deliver them directly to affected areas, effectively addressing the challenges posed by BBB permeability and systemic side effects [68,69]. These systems utilize mechanisms such as receptor-mediated transport and stimuli-responsive release to enhance therapeutic efficacy while minimizing adverse effects [70]. Overall, the integration of nanotechnology in treating brain diseases represents a promising frontier in neuropharmacology, with ongoing research aimed at optimizing these innovative delivery systems.

The translation of nanobot technology from preclinical stages to human trials faces several key regulatory challenges. Firstly, the lack of clear and consolidated regulatory guidance complicates the development process, as it is essential to identify critical quality attributes and ensure appropriate analytical methods for characterization [88]. Additionally, extensive in vitro and in vivo trials are mandated to address safety and efficacy concerns, which can be resource-intensive [89]. The reproducibility of results and batch-to-batch consistency are also significant hurdles, as they are crucial for regulatory approval and successful manufacturing at scale [88,90]. Furthermore, the integration of autonomous nanomedicine technologies necessitates rigorous preclinical studies to validate their safety and effectiveness, while ethical considerations must be addressed to protect patient well-being [74]. Overall, close collaboration with regulatory agencies from early development stages is vital to navigate these challenges effectively [88].

➢ *Regulatory and Ethical Considerations*

The current FDA guidelines for the approval of nanomedicines and advanced therapeutic medicinal products emphasize the necessity for comprehensive safety and efficacy data, similar to traditional pharmaceuticals, while addressing the unique properties of nanoscale materials. Sponsors must submit New Drug Applications (NDA) or Abbreviated New Drug Applications (ANDA) that include detailed assessments of the nanomaterials' reactivity and potential toxicological impacts, as these characteristics can significantly influence safety profiles [92]. The FDA's draft guidance issued in 2017 outlines the regulatory pathways for products containing nanomaterials, highlighting the importance of determining critical quality attributes (CQAs) and the need for standardized characterization techniques [93,94]. Furthermore, ongoing discussions among stakeholders aim to refine these guidelines, ensuring they adapt to the evolving landscape of nanomedicine, which includes complex formulations like lipid nanoparticles and polymeric micelles [78].

The safety assessment of nanobots, particularly in the context of toxicology and immunogenicity, involves several key parameters that are crucial for their safe application in nanomedicine. The physicochemical properties of nanobots, such as size, shape, surface charge, and chemical composition, significantly influence their toxicity and bio kinetics, impacting their circulation and clearance in the body [96]. These properties are essential in determining the potential risk associated with nanobots, as they can affect cellular and molecular interactions leading to adverse biological effects [97]. The field of Nano toxicology plays a pivotal role in identifying these risks and developing strategies to mitigate them, integrating advanced analytical techniques like omics technologies to enhance understanding of nanotoxicity [98]. Furthermore, the dose, dose rate, and bio persistence of nanobots are critical factors in assessing their safety, as they can lead to undesirable effects if not properly managed [99]. Interdisciplinary collaborations among toxicologists, engineers, and clinicians are vital to ensure the responsible development of nanobots, addressing challenges such as human and environmental exposure and the potential for immunogenic responses [98,99]. A predictive toxicological paradigm, which focuses on mechanisms of injury at the cellular and molecular levels, is advocated to prioritize screening for adverse effects and ensure the safe application of nanobots in clinical settings [97]. Overall, a comprehensive safety assessment framework that considers these parameters is essential for the sustainable development and application of nanobots in medicine [100].

The deployment of highly autonomous nanobots presents both significant risks and benefits concerning individual privacy and societal control. On the one hand, these nanobots, akin to social robots, have the potential to collect vast amounts of sensitive personal data, which can be beneficial for decision-making and research purposes [101]. However, this data collection poses substantial privacy risks, as these autonomous entities can operate independently, forming beliefs and observational knowledge about individuals without human oversight, thereby diminishing privacy [102].

The legal framework currently does not adequately address the privacy implications of such autonomous systems, as they are not considered sentient and thus are often overlooked in privacy law [102]. On the other hand, there are efforts to mitigate these risks through the development of privacy-preserving architectures. For instance, computational systems are being designed to protect privacy by identifying and masking sensitive data in video streams, which could be applied to nanobots to ensure higher privacy protection for individuals [103]. Furthermore, the integration of privacy-aware robotics, which aligns with contextual norms and individual expectations, is crucial for the acceptance of these technologies in human environments [104]. Therefore, while the autonomous capabilities of nanobots offer promising advancements, they necessitate robust privacy safeguards and legal considerations to prevent potential societal control and privacy infringements.

VI. CONCLUSION

The integration of nanobots and Artificial Intelligence (AI) represents a transformative solution for overcoming the Blood-Brain Barrier (BBB) and revolutionizing the landscape of neurotherapeutics. The sources confirm that the BBB poses immense challenges to conventional drug delivery methods due to its selective permeability, specialized transport mechanisms, and additional barriers like the blood-cerebrospinal fluid barrier.

➢ *Synthesis of Key Findings*

Nanobots offer novel mechanisms for targeted drug delivery and navigation within the brain. Effective nanobot design requires the use of biocompatible materials that do not cause harmful reactions and biodegradable components that ensure safe clearance from the body after their task is complete. Nanobots can be propelled by various mechanisms, including chemical reactions, external forces such as magnetic fields or light, or by using potential field mechanisms that allow them to autonomously sense and respond to their environment, thereby moving toward disease areas and avoiding healthy tissues.

The integral role of AI is crucial for achieving unprecedented levels of precision and adaptability. AI algorithms, particularly machine learning models like ANNs, are used for optimizing design parameters such as stability and predicting therapeutic efficacy. Furthermore, AI-driven systems provide real-time control and autonomous navigation using advanced techniques like Hierarchical DRL to maneuver micro-robots through challenging vascular environments. This synergy enables highly targeted treatment for severe conditions, including the delivery of neurotrophic factors and gene editing tools for neurodegenerative diseases and enhanced precision in identifying tumor boundaries for brain tumors.

- *Implications for Future Research and Clinical Practice*

While the advancements are promising, significant hurdles remain in translating preclinical success to human trials. These include challenges in developing scalable and cost-effective manufacturing processes, standardizing preclinical testing protocols, and ensuring long-term safety profiles. Regulatory bodies, such as the FDA, require comprehensive safety and efficacy data, emphasizing the assessment of unique properties like reactivity and potential toxicological impacts of nanoscale materials. The deployment of highly autonomous nanobots also necessitates robust privacy safeguards and legal considerations to address the potential ethical implications regarding privacy and control.

- *Concluding Remarks and Outlook*

Realizing the transformative potential of this interdisciplinary field requires critical interdisciplinary collaboration between nanotechnology, AI, neuroscience, and clinical medicine. Addressing challenges such as the limited availability of comprehensive datasets and the need for Explainable AI to foster trust in nanobot behavior are vital for deepening the AI-nanobot synergy. The continued progression from fundamental research to clinical translation promises a future where intelligent nanomedicine fundamentally revolutionizes neurotherapeutics, leading to improved patient outcomes for complex brain disorders.

DECLARATION OF GENERATIVE AI AND AI-ASSISTED TECHNOLOGIES IN THE MANUSCRIPT PREPARATION PROCESS

During the preparation of this work, Patel Shrusti and Joshi Darshil used Chatgpt in order to summarize the whole data. After using Chatgpt, Patel Shrusti and Joshi Darshil reviewed and edited the content and take full responsibility for the content of the published article.

REFERENCES

[1]. Werner C, Mathkour M, Tubbs RS. Chapter 16 - The blood brain barrier. In: Tubbs RS, Iwanaga J, Rizk EB, D'Antoni AV, Dumont AS, editors. Cerebrospinal Fluid and Subarachnoid Space [Internet]. Academic Press; 2023 [cited 2025 Aug 13]. p. 229–44. https://www.sciencedirect.com/science/article/pii/B9780128195093000146

[2]. Hatwar PR, Tajne PS, Kalamb VS, Bakal RL. Blood-Brain Barrier: A Comprehensive Review of Its Structure, Function and Role in CNS Diseases. IJFMR - Int J Multidiscip Res [Internet]. 2025 Jan 4 [cited 2025 Aug 13];7(1). https://www.ijfmr.com/research-paper.php?id=34551

[3]. Benz F, Liebner S. Structure and Function of the Blood–Brain Barrier (BBB). In: Cader Z, Neuhaus W, editors. Physiology, Pharmacology and Pathology of the Blood-Brain Barrier [Internet]. Cham: Springer International Publishing; 2022 [cited 2025 Aug 13]. p. 3–31. https://doi.org/10.1007/164_2020_404

[4]. Can B, Alataş İÖ. The blood-brain barrier: a focus on neurovascular unit components. Eur J Life Sci. 2024 Dec 31;3(3):127-35.

[5]. Basement membrane and blood–brain barrier | Stroke and Vascular Neurology [Internet]. [cited 2025 Aug 13]. https://svn.bmj.com/content/4/2/78

[6]. Adkins CE, Barber KR, Lockman PR. Crossing the barrier: The role of the blood–brain barrier in treating mental illness. The Biochemist. 2013 June 1;35(3):4–8.

[7]. Lalatsa A, Butt AM. Chapter 3 - Physiology of the Blood–Brain Barrier and Mechanisms of Transport Across the BBB. In: Kesharwani P, Gupta U, editors. Nanotechnology-Based Targeted Drug Delivery Systems for Brain Tumors [Internet]. Academic Press; 2018 [cited 2025 Aug1 3]. p.49–74. https://www.sciencedirect.com/science/article/pii/B9780128122181000038

[8]. Kerns EH, Di L. Chapter 10 - Blood-Brain Barrier. In: Kerns EH, Di L, editors. Drug-like Properties: Concepts, Structure Design and Methods [Internet]. San Diego: Academic Press; 2008 [cited 2025 Aug 13]. p. 122–36. https://www.sciencedirect.com/science/article/pii/B9780123695208500115

[9]. Kodous AS, Ramanathan P, Rao AKDM, Atia GAN. Challenges in Brain Targeting and Mechanisms of Drug Transfer across the BBB. In: Nanocarriers in Neurodegenerative Disorders. CRC Press; 2024.

[10]. The Mechanism and Latest Research Progress of Blood–Brain Barrier Breakthrough [Internet]. [cited 2025 Aug 13]. https://www.mdpi.com/2227-9059/12/10/2302

[11]. Partridge B, Eardley A, Morales BE, Campelo SN, Lorenzo MF, Mehta JN, et al. Advancements in drug delivery methods for the treatment of brain disease. Front Vet Sci [Internet]. 2022 Oct 18 [cited 2025 Aug13];9.https://www.frontiersin.org/journals/veterinary-science/articles/10.3389/fvets.2022.1039745/ full

[12]. Mansor NI, Nordin N, Mohamed F, Ling KH, Rosli R, Hassan Z. Crossing the Blood-Brain Barrier: A Review on Drug Delivery Strategies for Treatment of the Central Nervous System Diseases. http://www.eurekaselect.com [Internet]. https://www.eurekaselect.com/article/100498

[13]. Kotha AK, Ghosh S, Komanduri N, Wang R, Bhowmick S, Chougule MB. Approaches in Barriers, Modifications, Route of Administrations, and Formulations of Therapeutic Agents for Brain Delivery. In: Misra A, Shahiwala A, editors. Novel Drug Delivery Technologies: Innovative Strategies for Drug Re-positioning [Internet]. Singapore: Springer; 2019 [cited 2025 Aug 13]. p. 383–401. https://doi.org/10.1007/978-981-13-3642-3_11

[14]. admin. BRAIN DRUG DELIVERY SYSTEM: A COMPREHENSIVE REVIEW ON RECENT EXPERIMENTAL AND CLINICAL FINDINGS | INTERNATIONAL JOURNAL OF PHARMACEUTICAL SCIENCES AND RESEARCH [Internet]. 2011 [cited 2025 Aug 13]. https://ijpsr.com/bft-article/brain-drug-delivery-system-a-comprehensive- review-on-recent-experimental-and-clinical-findings/?view=fulltext

[15]. ajpsonline.com/HTML_Papers/Asian Journal of Research in Pharmaceutical Sciences PID 2023-13-1-4.html [Internet]. [cited 2025 Oct 16]. https://ajpsonline.com/HTML_Papers/Asian%20Journal%20of%20Research%20in%20Pharmaceutical%20Sciences PID 2023-13-1-4.html

[16]. Kishore AMV. The Promising Future in Medicine: Nanorobots [Internet]. [cited 2025 Oct 16]. https://www.researchgate.net/publication/275155401_The_Promising_Future_in_Medicine_N anorobots

[17]. Shivalkar S, Chowdhary P, Afshan T, Chaudhary S, Roy A, Samanta SK, et al. Nanoengineering of biohybrid micro/nanobots for programmed biomedical applications. Colloids Surf B Biointerfaces. 2023 Feb 1; 222:113054.

[18]. Soto F, Wang J, Ahmed R, Demirci U. Medical Micro/Nanorobots in Precision Medicine. Adv Sci. 2020;7(21):2002203.

[19]. Yang L, Wang H, Leng D, Fang S, Yang Y, Du Y. Machine learning applications in nanomaterials: Recent advances and future perspectives. Chem Eng J. 2024 Nov 15; 500:156687.

[20]. Hundekari DS, Prakash DJ, Choudari S, Asaduzzaman 4Md, Koley 5Bijoy Laxmi, Biswas 6Anupam Kumar, et al. Machine Learning-Driven Nanomaterial Design: Predictive Modeling for Enhanced Performance in Electronics. Nanotechnol Percept. 2024 Nov 4;2039–51.

[21]. Muneer R, Hashmet MR, Pourafshary P, Shakeel M. Unlocking the Power of Artificial Intelligence: Accurate Zeta Potential Prediction Using Machine Learning. Nanomaterials. 2023 Mar 29;13(7):1209.

[22]. Prabhu AM, Choksi TS. Data-driven methods to predict the stability metrics of catalytic nanoparticles. Curr Opin Chem Eng. 2022 June 1; 36:100797.

[23]. Raja S, Amin I, Pedregosa F, Krishnapriyan AS. Stability-Aware Training of Machine Learning Force Fields with Differentiable Boltzmann Estimators [Internet]. arXiv; 2025 [cited 2025 Aug 2]. http://arxiv.org/abs/2402.13984

[24]. SciSpace - Paper [Internet]. 2023 [cited 2025 Aug 2]. p. 1–5 Application of Machine Learning and Hyper-Parameter Optimisation for Efficient Prediction of Transient Stability. https://scispace.com/papers/application-of-machine-learning-and-hyper- parameter-3pw4t6xcvq

[25]. SciSpace - Paper [Internet]. 2023 [cited 2025 Aug 2]. p. 57–65 Robotic Demonstration Learning Stability-Accuracy Trade-Off: From an Energy Function Learning Viewpoint. https://scispace.com/papers/robotic-demonstration-learning-stability-accuracy- trade-off-4f4baxwzhi

[26]. Novitskiy L, Lazarev V, Tiutiulnikov M, Vakhrameev N, Eremin R, Humonen I, et al. Unleashing the power of novel conditional generative approaches for new materials discovery [Internet]. arXiv; 2024 [cited 2025 Aug 2]. http://arxiv.org/abs/2411.03156

[27]. SciSpace - Paper [Internet]. arXiv (Cornell University); 2022 [cited 2025 Aug 2]. High-throughput property-driven generative design of functional organic molecules. https://scispace.com/papers/high-throughput-property-driven-generative-design-of-7jxasxgw

[28]. Inverse Design of Crystal Compositions via Improved Generative Models | IEEE Conference Publication | IEEE Xplore [Internet]. [cited 2025 Aug 2]. https://ieeexplore.ieee.org/document/10771039

[29]. Constrained crystals deep convolutional generative adversarial network for the inverse design of crystal structures | npj Computational Materials [Internet]. [cited 2025 Aug 2]. https://www.nature.com/articles/s41524-021-00526-4

[30]. Fuhr AS, Sumpter BG. Deep Generative Models for Materials Discovery and Machine Learning-Accelerated Innovation. Front Mater [Internet]. 2022 Mar 22 [cited 2025 Aug 2];9. https://www.frontiersin.org/journals/materials/articles/10.3389/fmats.2022.865270/full

[31]. Ayuba A, Tera T, Kelvin L. AI-Driven High-Throughput Screening for Targeted Drug Discovery [Internet]. OSF; 2023 [cited 2025 Aug 2]. https://osf.io/3brga_v1

[32]. AI-Powered Virtual Screening of Large Compound Libraries Leads to the Discovery of Novel Inhibitors of Sirtuin-1 | Journal of Medicinal Chemistry [Internet]. [cited 2025 Aug 2]. https://pubs.acs.org/doi/10.1021/acs.jmedchem.3c00128

[33]. AI-driven drug discovery: identification and optimization of ALDH3A1 selective inhibitors with nanomolar activity | Theoretical and Computational Chemistry | ChemRxiv | Cambridge Open Engage [Internet]. [cited 2025 Aug 2]. https://chemrxiv.org/engage/chemrxiv/article-details/672190417be152b1d039cae7

[34]. Exploring the Artificial Intelligence and Its Impact in Pharmaceutical Sciences: Insights Toward the Horizons Where Technology Meets Tradition -

Bharadwaj - 2024 - Chemical Biology & Drug Design - Wiley Online Library [Internet]. [cited 2025 Aug 2]. https://onlinelibrary.wiley.com/doi/10.1111/cbdd.14639
[35]. Sharma R, Siddhartha M, Ghazi ME, Pal M. Advancement in medical imaging: nanotechnology. 2024 Feb 28;
[36]. Engineering Intelligent Nanosystems for Enhanced Medical Imaging - van Moolenbroek - 2020 - Advanced Intelligent Systems - Wiley Online Library [Internet]. [cited 2025 Aug 3]. https://advanced.onlinelibrary.wiley.com/doi/10.1002/aisy.202000087
[37]. Zhu C, Sun J. Intelligent Magnetic Resonance Imaging analysis and processing technology for magnetic nanoparticles medical applications. In: Proceedings of the 2023 15th International Conference on Bioinformatics and Biomedical Technology [Internet]. New York, NY, USA: Association for Computing Machinery; 2023 [cited 2025 Aug 3]. p. 34–9. (ICBBT '23). https://doi.org/10.1145/3608164.3608169
[38]. Phase-contrast visualization of human tissues using superimposed wavefront imaging of diffraction-enhanced x-rays - Sunaguchi - 2024 - Medical Physics - Wiley Online Library [Internet]. https://aapm.onlinelibrary.wiley.com/doi/10.1002/mp.17336
[39]. Chakraborty S, Misra B, Mridha MF. Enhancing Intelligent Medical Imaging to Revolutionize Healthcare. In: Smart Medical Imaging for Diagnosis and Treatment Planning. Chapman and Hall/CRC; 2024.
[40]. Yang Y, Bevan MA, Li B. Hierarchical deep reinforcement learning controlled three- dimensional navigation of microrobots in blood vessels.
[41]. Yang Y, Bevan MA, Li B. Hierarchical Planning with Deep Reinforcement Learning for 3D Navigation of Microrobots in Blood Vessels. Adv Intell Syst. 2022 Nov;4(11):2200168.
[42]. Zhang C, Dong L, Sun C. Reinforcement Learning with Evolutionary Computation to Policy Search for Autonomous Navigation. In: 2020 35th Youth Academic Annual Conference of Chinese Association of Automation (YAC) [Internet]. Zhanjiang, China: IEEE; 2020 [cited 2025 Aug 3]. p. 288–92. https://ieeexplore.ieee.org/document/9337605/
[43]. Morayo Ogunsina, Christianah Pelumi Efunniyi, Olajide Soji Osundare, Samuel Olaoluwa Folorunsho, Lucy Anthony Akwawa. Reinforcement learning in autonomous navigation: Overcoming challenges in dynamic and unstructured environments. Eng Sci Technol J. 2024 Sept 5;5(9):2724–36.
[44]. Pokkuluri KS, N UD, Khang A, Pokkuluri KS, N UD, Khang A. https://services.igi-global.com/resolvedoi/resolve.aspx?doi=10.4018/979-8-3693-2069-3.ch009. IGI Global Scientific Publishing; 1 AD [cited 2025 Aug 3]. Integration of Machine Learning Augmented With Biosensors for Enhanced Water Quality Monitoring. https://www.igi-global.com/gateway/chapter/www.igi-global.com/gateway/chapter/337572
[45]. Wang X. Artificial intelligence enhanced environmental detection system. Appl Comput Eng. 2024 May 29;66(1):156–9.
[46]. Zhou Z, Xu T, Zhang X. Empowerment of AI algorithms in biochemical sensors. TrAC Trends Anal Chem. 2024 Apr 1; 173:117613.
[47]. Thapa R, Poudel S, Krukiewicz K, Kunwar A. A topical review on AI-interlinked biodomain sensors for multi-purpose applications. Measurement. 2024 Mar 15; 227:114123.
[48]. Subcellular Drug Distribution: Exploring Organelle-Specific Characteristics for Enhanced Therapeutic Efficacy [Internet]. [cited 2025 Aug 3]. https://www.mdpi.com/1999-4923/16/9/1167
[49]. Predicting drug metabolism: experiment and/or computation? |Nature Reviews Drug Discovery [Internet]. [cited 2025 Aug 3]. https://www.nature.com/articles/nrd4581.epdfsharing_token=VWMzNnjFmOEdQmaqhxlewNRgN0jAjWel9jnR3ZoTv0Nv1ck_59ji5jh5qSYbcfEFIJsYkVTRQ5Gc1BI_kXzBJJUoKCqn_sYI7pca9pNqEQVraH0vxm8dpZSTz6IbuTprbxVmlzpQFOkk_EX5zci2z58HC3DfsjXDWF8AXncRs3VgewHapZZYtdXxjEto3rII3QRXfUEgnFju1reGPegw%3D3D&tracking_referrer=scispace.com
[50]. Artificial Intelligence in Drug Metabolism and Excretion Prediction: Recent Advances, Challenges, and Future Perspectives [Internet]. [cited 2025 Aug 3]. https://www.mdpi.com/1999-4923/15/4/1260
[51]. Stepensky D. Prediction of Drug Disposition on the Basis of its Chemical Structure. Clin Pharmacokinet. 2013 June 1;52(6):415–31.
[52]. Periyasamy M. Integrating Machine Learning in Pre-Clinical Research for Predictive Analytics in Drug Development. In: 2024 First International Conference for Women in Computing (InCoWoCo) [Internet]. 2024 [cited 2025 Aug 3]. p. 1–9. https://ieeexplore.ieee.org/document/10863152
[53]. Artificial intelligence for personalized nanomedicine; from material selection to patient outcomes: Expert Opinion on Drug Delivery: Vol 22, No 1 - Get Access [Internet]. [cited 2025 Aug 3]. https://www.tandfonline.com/doi/full/10.1080/17425247.2024.2440618
[54]. Kavousinejad S. Simulation of Nanorobots with Artificial Intelligence and Reinforcement Learning for Advanced Cancer Cell Detection and Tracking [Internet]. arXiv; 2024 [cited 2025 Aug 3]. http://arxiv.org/abs/2411.02345
[55]. #36482 Revolutionizing nerve pain treatment: harnessing dosimetry, nanobots, and ai for personalized relief | Regional Anesthesia & Pain Medicine [Internet]. [cited 2025 Aug 3]. https://rapm.bmj.com/content/48/Suppl_1/A211.1
[56]. S S, R D, P S, P N. Revolutionizing Cancer Therapy: Artificial Intelligence-Controlled Nanorobots for Precise and Non-Invasive Tumor Eradication [Internet]. Research Square; 2024 [cited 2025 Aug 3]. https://www.researchsquare.com/article/rs-4196654/v1
[57]. Saleh Z, Jaber W, Jaber A, Cheble E, Bechelany M, Hijazi A, et al. https://services.igi-

global.com/resolvedoi/resolve.aspx?doi=10.4018/979-8-3693-0368-9.ch007. IGI Global Scientific Publishing; 1 AD [cited 2025 Aug 3]. Utilizing AI and Nanotechnology Solutions to Propel Progress in Cancer Diagnostics, Therapeutics, and Integrated Theranostics. https://www.igi-global.com/gateway/chapter/www.igi-global.com/gateway/chapter/ 334937

[58]. Recent Advances in Omics, Computational Models, and Advanced Screening Methods for Drug Safety and Efficacy [Internet]. [cited 2025 Aug 3]. https://www.mdpi.com/2305-6304/12/11/822

[59]. Lutnick B, Ramon AJ, Ginley B, Csiszer C, Kim A, Flament I, et al. Accelerating pharmaceutical R&D with a user-friendly AI system for histopathology image analysis. J Pathol Inform. 2023 Jan 1; 14:100337.

[60]. Song X, Li C, Meng Y. Mass spectrometry imaging advances and application in pharmaceutical research. Acta Mater Medica. 2022 Dec 23; 1:507–33.

[61]. Batta I, Patial R, Sobti RC, Agrawal DK. Computational Biology in the Discovery of Biomarkers in the Diagnosis, Treatment and Management of Cardiovascular Diseases. Cardiol Cardiovasc Med. 2024 Sept 5;8(5):405–14.

[62]. Gawade P, Nandi S, Meena C, Sarkar RR. Artificial Intelligence and Machine Learning Techniques Using Omics Data for Cancer Diagnosis and Treatment. In: Singh S, editor. Systems Biomedicine Approaches in Cancer Research [Internet]. Singapore: Springer Nature; 2022 [cited 2025 Aug 3]. p. 23–50. https://doi.org/10.1007/978-981-19-1953- 4_2

[63]. Transparent Exploration of Machine Learning for Biomarker Discovery from Proteomics and Omics Data | Journal of Proteome Research [Internet]. [cited 2025 Aug 3]. https://pubs.acs.org/doi/10.1021/acs.jproteome.2c00473

[64]. Raikar G (Vedant) S, Raikar AS, Somnache SN. Advancements in artificial intelligence and machine learning in revolutionising biomarker discovery. Braz J Pharm Sci. 2023 Aug 28;59:e23146.

[65]. Tang L, Li J, Zhao Q, Pan T, Zhong H, Wang W. Advanced and Innovative Nano-Systems for Anticancer Targeted Drug Delivery. Pharmaceutics. 2021 Aug;13(8):1151.

[66]. Zhu J, Lee H, Huang R, Zhou J, Zhang J, Yang X, et al. Harnessing nanotechnology for cancer treatment. Front Bioeng Biotechnol [Internet]. 2025 Jan 20 [cited 2025 Aug 5];12. https://www.frontiersin.org/journals/bioengineering-and-biotechnology/articles/ 10.3389/fbioe.2024.1514890/full

[67]. Bhatia R, Sharma A, Narang RK, Rawal RK. Recent Nanocarrier Approaches for Targeted Drug Delivery in Cancer Therapy. Curr Mol Pharmacol. 14(3):350–66.

[68]. Tiwari H, Gupta P, Verma A, Singh S, Kumar R, Gautam HK, et al. Advancing Era and Rising Concerns in Nanotechnology-Based Cancer Treatment. ACS Chem Health Saf. 2024 Mar 25;31(2):153–61.

[69]. Weerarathna IN, Kamble AR, Luharia A, Weerarathna IN, Kamble AR, Luharia A. Artificial Intelligence Applications for Biomedical Cancer Research: A Review. Cureus [Internet]. 2023 Nov 5 [cited 2025 Aug 5];15(11). Available from: https://cureus.com/articles/204269-artificial-intelligence-applications-for-biomedical-cancer-research-a-review

[70]. Artificial intelligence-driven precision medicine in cancer treatment - Premier Science [Internet]. 2024 [cited 2025 Aug 5]. https://premierscience.com/pjs-24-387/

[71]. Sabrouty RE, Elouadi A. Harnessing AI for Precision Oncology: Transformative Advances in Non-Small Cell Lung Cancer Treatment. Stat Optim Inf Comput. 2025;13(1):347–67.

[72]. Akter S. AI-Driven Precision Medicine: Transforming Personalized Cancer Treatment. J AI- Powered Med Innov Int Online ISSN 3078-1930. 2024 Oct 5;2(1):10–21.

[73]. Wang A, Huang J, Ji M, Huang Y, Chen L, Peng Y, et al. Membrane Budding Inspired Biomimetic Nanocarrier Delivers Brain-derived Neurotrophic Factor to Improve AD Cognition. Adv Funct Mater. 2025;35(10):2416572.

[74]. Musallam S, Poustinchi M. Nano-Power Implantable Autonomous Closed-Loop CMOS Nerve-Growth-Factor Delivery Microsystem for Neurological Disorders Personalized Therapy. 2014;2.

[75]. Singh AV, Chandrasekar V, Janapareddy P, Mathews DE, Laux P, Luch A, et al. Emerging Application of Nanorobotics and Artificial Intelligence To Cross the BBB: Advances in Design, Controlled Maneuvering, and Targeting of the Barriers. ACS Chem Neurosci. 2021 June 2;12(11):1835–53.

[76]. Rai A, Shah K, Dewangan HK. Review on the Artificial Intelligence-based Nanorobotics Targeted Drug Delivery System for Brain-specific Targeting. http://www.eurekaselect.com [Internet]. [cited 2025 Aug 5]; https://www.eurekaselect.com/article/136727

[77]. He S, Abarrategi JS, Bediaga H, Arrasate S, González-Díaz H. On Additive Artificial Intelligence Discovery of Nanoparticle-Neurodegenerative Disease Drug Delivery Systems. Beilstein Arch. 2024 Feb 15;2024(1):10.

[78]. Review on the Artificial Intelligence-based Nanorobotics Targeted Drug Delivery System for Brain-specific Targeting | Bentham Science [Internet]. [cited 2025 Aug 7]. https://www.eurekaselect.com/article/136727

[79]. Saniotis A, Henneberg M, Sawalma AR. Integration of Nanobots into Neural Circuits as a Future Therapy for Treating Neurodegenerative Disorders. Front Neurosci [Internet]. 2018 Mar 21 [cited 2025 Aug 7];12. https://www.frontiersin.org/journals/neuroscience/articles/10.3389/fnins.2018.00153/full

[80]. Enhancing Therapeutic Delivery Using Micro- and Nanorobots | IEEE Journals & Magazine | IEEE Xplore [Internet]. [cited 2025 Aug 7]. https://ieeexplore.ieee.org/document/10136361

[81]. Targeted Drug Delivery: From Chemistry to Robotics

at Small Scales | Annual Reviews [Internet].[cited 2025 Aug 7]. https://www.annualreviews.org/content/journals/10.1146/annurev-control-022823-034402

[82]. Zhao Q, Lin L. Modeling and Simulation of a Bio-Inspired Nanorobotic Drug Delivery System. In: Chen Y, Yao D, Nakano T, editors. Bio-inspired Information and Communications Technologies. Cham: Springer Nature Switzerland; 2023. p. 64–76.

[83]. Panda V, Saindane A, Pandey A. Nanobots: Revolutionising the Next Generation of Biomedical Technology and Drug Therapy. http://www.eurekaselect.com [Internet]. [cited 2025 Aug 7]; https://www.eurekaselect.com/article/133140

[84]. Rai A, Shah K, Dewangan HK. Review on the Artificial Intelligence-based Nanorobotics Targeted Drug Delivery System for Brain-specific Targeting. http://www.eurekaselect.com [Internet]. [cited 2025 Aug 8]; https://www.eurekaselect.com/article/136727

[85]. Nady DS, Bakowsky U, Fahmy SA. Recent advances in brain delivery of synthetic and natural nano therapeutics: Reviving hope for Alzheimer's disease patients. J Drug Deliv Sci Technol. 2023 Nov 1;89:105047.

[86]. Nanomedicines for Alzheimer's disease: Therapies based on pathological mechanisms – Cheng 2023 - Brain-X - Wiley Online Library [Internet]. [cited 2025 Aug 8]. https://onlinelibrary.wiley.com/doi/10.1002/brx2.27

[87]. Toader C, Dumitru AV, Eva L, Serban M, Covache-Busuioc RA, Ciurea AV. Nanoparticle Strategies for Treating CNS Disorders: A Comprehensive Review of Drug Delivery and Theranostic Applications. Int J Mol Sci. 2024 Jan;25(24):13302.

[88]. Đorđević S, Gonzalez MM, Conejos-Sánchez I, Carreira B, Pozzi S, Acúrcio RC, et al. Current hurdles to the translation of nanomedicines from bench to the clinic. Drug Deliv Transl Res. 2022 Mar 1;12(3):500–25.

[89]. Bellare JR. Nanotechnology and Nanomedicine for Healthcare: Challenges in Translating Innovations from Bench to Bedside. J Biomed Nanotechnol. 2011 Jan 1;7(1):36–7.

[90]. Hua S, de Matos MBC, Metselaar JM, Storm G. Current Trends and Challenges in the Clinical Translation of Nanoparticulate Nanomedicines: Pathways for Translational Development and Commercialization. Front Pharmacol [Internet]. 2018 July 17 [cited 2025 Aug 8];9. https://www.frontiersin.org/journals/pharmacology/articles/10.3389/fphar.2018.00790/ full

[91]. Chohan DP, Dey B, Tarkunde A, Vyas V, De Sarkar S, Sundara BK. Advancing Autonomous Nanomedicine: Bridging the Gap from Concept to Potential Clinical Studies. J Clust Sci. 2024 Dec 1;35(8):2607–35.

[92]. Rahman Z, Charoo NA, Akhter S, Beg S, Reddy IK, Khan MA. Nanotechnology-based drug products. In: Nanoscale Fabrication, Optimization, Scale-Up and Biological Aspects of Pharmaceutical Nanotechnology [Internet]. Elsevier; 2018 [cited 2025 Aug 8]. p. 619–55. https://linkinghub.elsevier.com/retrieve/pii/B9780128136294000164

[93]. Souto EB, Blanco-Llamero C, Krambeck K, Kiran NS, Yashaswini C, Postwala H, et al. Regulatory insights into nanomedicine and gene vaccine innovation: Safety assessment, challenges, and regulatory perspectives. Acta Biomater. 2024 May 1;180:1–17.

[94]. de Vlieger JSB, Crommelin DJA, Tyner K, Drummond DC, Jiang W, McNeil SE, et al. Report of the AAPS Guidance Forum on the FDA Draft Guidance for Industry: "Drug Products, Including Biological Products, that Contain Nanomaterials." AAPS J. 2019 Apr 17;21(4):56.

[95]. Bobo D, Robinson KJ, Islam J, Thurecht KJ, Corrie SR. Nanoparticle-Based Medicines: A Review of FDA-Approved Materials and Clinical Trials to Date. Pharm Res. 2016 Oct 1;33(10):2373–87.

[96]. Biosafety - Biomedical Micro- and Nanorobots in Disease Treatment - Wiley Online Library [Internet]. [cited 2025 Aug 8]. https://onlinelibrary.wiley.com/doi/10.1002/9783527839773.ch5

[97]. Meng H, Xia T, George S, Nel AE. A Predictive Toxicological Paradigm for the Safety Assessment of Nanomaterials. ACS Nano. 2009 July 28;3(7):1620–7.

[98]. Adhikary B, Mishra HG, Sahu BB, Kumar LA. NANOTOXICOLOGY: SAFETY ASSESSMENT AND RISK EVALUATION OF NANOMEDICINE. In: Rather LJ, PatilmDrAB, Mondi DrPR, Jena BR, R DrN, Mech DrB, et al., editors. Futuristic Trends in Chemical Material Sciences & Nano Technology Volume 3 Book 19 [Internet]. Iterative International Publishers, Selfypage Developers Pvt Ltd; 2024 [cited 2025 Aug 8]. p. 70–80. https://www.iipseries.org/viewpaper.php?pid=1898&pt=nanotoxicology-safety-assessment- and-risk-evaluation-of-nanomedicines

[99]. Oberdörster G. Safety assessment for nanotechnology and nanomedicine: concepts of nanotoxicology. J Intern Med. 2010;267(1):89–105.

[100]. Fadeel B, editor. Handbook of Safety Assessment of Nanomaterials: From Toxicological Testing to Personalized Medicine. New York: Jenny Stanford Publishing; 2014. 562 p.

[101]. Dorafshanian M, Aitsam M, Mejri M, Di Nuovo A. Beyond Data Collection: Safeguarding User Privacy in Social Robotics. In: 2024 IEEE International Conference on Industrial Technology (ICIT) [Internet]. 2024 [cited 2025 Aug 13]. p. 1–6. https://ieeexplore.ieee.org/document/10540743

[102]. Schrödinger's Robot: Privacy in Uncertain States. Soc Sci Res Netw [Internet]. 2018 Apr 12 [cited 2025 Aug 13]; https://scispace.com/papers/schrodinger-s-robot-privacy- in-uncertain-states-4kudf1cklg

[103]. Wagner AR. An Autonomous Architecture that Protects the Right to Privacy. In: Proceedings of the 2018 AAAI/ACM Conference on AI, Ethics, and Society [Internet]. New York, NY, USA: Association for Computing Machinery; 2018 [cited 2025 Aug 13].

p. 330–4. (AIES ’18). https://doi.org/10.1145/3278721.3278768

[104]. Levinson L, Dietrich M, Sarkisian A, Sabanovic S, Smart WD. Privacy Aware Robotics. In: Companion of the 2024 ACM/IEEE International Conference on Human-Robot Interaction [Internet]. New York, NY, USA: Association for Computing Machinery; 2024 [cited 2025 Aug 13]. p. 1335–7. (HRI ’24). https://doi.org/10.1145/3610978.3638161